Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study

AbstractPurposeThe aim of this study was to identify and characterize immune checkpoint inhibitors (ICIs)-associated pituitary adverse events (AEs).MethodsThis is a retrospective disproportionality study based on VigiBase, the World Health Organization (WHO) global database of individual case safety reports (ICSRs), with a study period from January 1, 2011 to March 6, 2019. Information component (IC) and reporting odds ratio (ROR) are measures of disproportionate analysis. IC was used to evaluate the association between ICIs and pituitary AEs, while ROR was used to evaluate the differences in reporting of pituitary AEs between different ICI subgroups.ResultsThe following ICI-associated pituitary diseases have been increasingly reported: hypophysitis (835 reports; information component 6.74 [95% CI 6.63 –6.83]), hypopituitarism (268; 6.12 [95% CI 5.92–6.27]), pituitary enlargement (28; 5.19 [95% CI 4.57–5.63]). The anti-CTLA-4 subgroup had a stronger association with hypophysitis/hypopituitarism than the anti-PD (anti-PD-1 or anti-PD-L1) subgroup (ROR 8.0 [95% CI 6.7–9.6]). Among ICI-assoc iated hypophysitis/hypopituitarism cases, the proportion of male was higher than female (630 [63.9%] vs 356 [36.1%]). Anti-CTLA-4 subgroup and ICI combination (nivolumab plus ipilimumab) subgroup both had a significantly earlier onset time than anti-PD subgroup (67 days [IQR 48–87]; 90 [IQR 34– 155]; 140 [IQR 62–218], bothp 
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research

Related Links:

Publication date: Available online 22 May 2020Source: EXPLOREAuthor(s): Pritha Mehra, Bindu Sharma, Hafeezulla Baig, Ch. Raveendar, R.V.R. Prasad, M.Prakash Rao, Kolli Raju, J.S. Arya, Raj K. Manachanda, Daisy Katarmal, Arvind Kumar
Source: EXPLORE: The Journal of Science and Healing - Category: Complementary Medicine Source Type: research
Authors: Ameratunga R, Lehnert K, Leung E, Comoletti D, Snell R, Woon ST, Abbott W, Mears E, Steele R, McKee J, Muscroft-Taylor A, Ameratunga S, Medlicott N, Das S, Rolleston W, Quiñones-Mateu M, Petousis-Harris H, Jordan A Abstract COVID-19 is a new zoonotic disease caused by the SARS-CoV-2 virus. Since its emergence in Wuhan City, China, the virus has rapidly spread across the globe causing calamitous health, economic and societal consequences. It causes disproportionately severe disease in the elderly and those with co-morbidities, such as hypertension and diabetes. There is currently no proven treatment ...
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
Authors: Panoulas V, Kitas GD Abstract Introduction: Cardiovascular comorbidity is a major burden in patients with chronic inflammatory rheumatic diseases and a significant determinant of their outcome. In addition to optimal management of the underlying inflammatory condition according to current guidelines, individual cardiovascular risk factors, particularly dyslipidaemia, hypertension, and impaired glucose tolerance should be assessed regularly and guide risk stratification and requirement for treatment.Areas discussed: We critically reviewed manuscripts and guidelines on the pharmacological management of dysli...
Source: Expert Review of Clinical Pharmacology - Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research
Authors: Bertamini L, Bonello F, Boccadoro M, Bringhen S Abstract INTRODUCTION: . The last twenty years have introduced new therapeutic agents for multiple myeloma (MM); these include proteasome Inhibitors (PIs), immunomodulatory drugs (IMDs) and monoclonal antibodies (mAbs). However, MM remains incurable, hence there is an unmet need for new agents for the treatment of advanced refractory disease. New agents could also be used in early lines to achieve improved, more sustained remission. AREAS COVERED: . We review the most promising agents investigated in early-phase trials for the treatment of MM and provide ...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
Authors: Holly JMP, Biernacka K, Perks CM Abstract Introduction: Preclinical, clinical, and population studies have provided robust evidence for an important role for the insulin-like growth factor (IGF) system in the development of prostate cancer.Areas covered: An overview of the IGF system is provided. The evidence implicating the IGF system in the development of prostate cancer is summarized. The compelling evidence culminated in a number of clinical trials of agents targeting the system; the reasons for the failure of these trials are discussed.Expert opinion: Clinical trials of agents targeting the IGF system...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
CONCLUSION: We found an inverse association between 25(OH)D3 and mental health in patients with T2D at baseline. We found no association between 25(OH)D3 and vitality after adjustment. Future studies are needed to determine the association between vitamin D and mental well-being in patients with T2D. PMID: 32440752 [PubMed - as supplied by publisher]
Source: Hormones - Category: Endocrinology Tags: Hormones (Athens) Source Type: research
Condition:   Foot Ulcer, Diabetic Intervention:   Other: No intervention Sponsors:   Podimetrics, Inc.;   American Association of Diabetes Educators Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Mesotheliomas Pleural;   Malignant Pleural Mesothelioma Interventions:   Device: intrapleural photodynamic therapy with videothoracoscopy;   Drug: Nivolumab Injection Sponsors:   University Hospital, Lille;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 21 May 2020Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): Colm McElwain, Cathal M. McCarthy
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - Category: OBGYN Source Type: research
Abstract Immune checkpoint inhibitors have proven to be effective for various advanced neoplasia. Immune-related adverse events (irAEs) as a result of increased T cell activation are unique and potentially life-threating toxicities associated with the use of immune checkpoint inhibitors. Multiple endocrine irAEs, including primary hyperthyroidism and hypothyroidism, thyroiditis, primary adrenal insufficiency, type 1 diabetes mellitus, and hypophysitis, have been reported with the use of various immune checkpoint inhibitors. In some cases, these irAEs can lead to discontinuation of treatment. Here we propose for th...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
More News: Addison's Disease | Adrenal Insufficiency | Cancer & Oncology | Databases & Libraries | Diabetes | Diabetes Insipidus | Diabetes Mellitus | Endocrinology | Gastroenterology | Immunotherapy | International Medicine & Public Health | Study | Thyroid | WHO | Yervoy